Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Inclusion, innovation, and belonging
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Abu Dhabi Public Health Centre and Organon partner to enhance women’s health in Abu Dhabi

Save Print

May 30, 2025 7:22 am EDT

Abu Dhabi, 15 May 2025: The Abu Dhabi Public Health Centresigned an agreement withOrganon, a global healthcare company dedicated to advancing women’s health, at the 25th IUHPE World Conference on Health Promotion. Both entities will collaborate to enhance women’s health by focusing on key areas of intervention and addressing critical health challenges that uniquely or disproportionately affect women.

The agreement was signed by His Excellency Dr Rashed Alsuwaidi, Director General of the Abu Dhabi Public Health Centre and Ramy Koussa, Middle East, Turkey and Africa Associate Vice President at Organon. The agreement marks a shared commitment to advancing women’s health outcomes in Abu Dhabi.

The partnership aims to enhance women’s health and support a healthy pregnancy journey through various initiatives. These include delivering awareness campaigns, research and sharing insights on priority women’s health conditions. The collaboration will support the exchange of knowledge and expertise on key women’s health priorities, including cardiovascular, reproductive, and maternal health, improving healthcare for women in the emirate and driving meaningful health outcomes. The partnership will also deliver evidence-based educational resources that empower women throughout their health journey.

His Excellency Dr Rashed Alsuwaidi, Director General of ADPHC,said: “We are committed to prioritising the health of women and children as a cornerstone of our vision for a healthier future. Our goal is to create a supportive healthcare environment that empowers women throughout their lives, by not only addressing immediate health needs but also supporting long-term wellbeing and prevention, ensuring that every woman in the Emirate has access to exceptional, tailored healthcare, adopting a proactive and preventive approach to lead healthier, longer lives.

Ramy Koussa, META Associate Vice President at Organon, said: “We are privileged to partner with the Abu Dhabi Public Health Centre, reflecting our shared commitment to advancing the standard of healthcare for women in the emirate. At Organon, our commitment to being here for her health drives us to make a meaningful difference in women’s lives, and this agreement is a testament to our dedication to working collaboratively with government entities to achieve this goal. By uniting our expertise and resources, we strive to enhance the health and wellbeing of women across Abu Dhabi.

“This partnership underscores our dedication to addressing critical challenges in women’s health both here in the UAE and throughout the MENA region. By combining our expertise with the leadership of the Abu Dhabi Public Health Centre, we aim to create impactful programmes that support women at every stage of their health journey. This collaboration will complement our broader efforts throughout the MENA region to advance women’s health in several areas such as cardiovascular health and chronic conditions like migraine.” Organon will also work closely with the Abu Dhabi Public Health Centre to organise educational forums, counselling sessions, and training workshops aimed at empowering women with the knowledge and resources they need to make informed health decisions. By integrating efforts and exchanging expertise, Organon aims to strengthen the support system for women across various aspects of their health, ensuring a holistic approach to their wellbeing.

What can we help you find?

Search for:
META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept